

Special Issue

Recent Discoveries and Developments in RNA and DNA Vaccines

Message from the Guest Editor

With a long history of humans fighting against disease, scientists developed a biological preparation called a vaccine during the 10th century. A vaccine provides an active acquired immunity to a particular infectious or malignant disease. The effectiveness and safety of vaccines are always a significant concern to humankind; thus, scientists have undertaken considerable efforts and performed many pre-clinical and clinical studies to verify these in the last 60 years. RNA or DNA vaccine discovery and development for preventive and therapeutic applications has evolved rapidly in the previous decade. This Special Issue will focus on the most recent advanced research related to RNA or DNA vaccine discovery and development for preventive and therapeutic applications to fight against infectious or malignant diseases. The safest and most efficient RNA or DNA applications underlining the advantages and disadvantages of current RNA or DNA vaccines will be discussed. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome.

Guest Editor

Prof. Dr. Hang Fai (Henry) Kwok

1. Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 999078, China
2. Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR 999078, China

Deadline for manuscript submissions

closed (31 July 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/184613

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).